Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Do toxic synthetic cannabinoid receptor agonists have signature in vitro activity profiles? A case study of AMB-FUBINACA.

Finlay DB, Manning JJ, Ibsen MS, Macdonald CE, Patel M, Javitch JA, Banister SD, Glass M.

ACS Chem Neurosci. 2019 Sep 12. doi: 10.1021/acschemneuro.9b00429. [Epub ahead of print]

PMID:
31513380
2.

Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonists.

Wouters E, Walraed J, Banister SD, Stove CP.

Biochem Pharmacol. 2019 Aug 28;169:113623. doi: 10.1016/j.bcp.2019.08.025. [Epub ahead of print] Review.

PMID:
31472128
3.

In vitro determination of the CB1 efficacy of illicit synthetic cannabinoids.

Sachdev S, Vemuri K, Banister SD, Longworth M, Kassiou M, Santiago M, Makriyannis A, Connor M.

Br J Pharmacol. 2019 Aug 14. doi: 10.1111/bph.14829. [Epub ahead of print]

PMID:
31412133
4.

Selective modulation of the cannabinoid type 1 (CB1) receptor as an emerging platform for the treatment of neuropathic pain.

Banister SD, Krishna Kumar K, Kumar V, Kobilka BK, Malhotra SV.

Medchemcomm. 2019 Mar 18;10(5):647-659. doi: 10.1039/c8md00595h. eCollection 2019 May 1. Review.

PMID:
31191856
5.

CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor Agonist.

Kevin RC, Anderson L, McGregor IS, Boyd R, Manning JJ, Glass M, Connor M, Banister SD.

Front Pharmacol. 2019 May 29;10:595. doi: 10.3389/fphar.2019.00595. eCollection 2019.

6.

The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogs.

Banister SD, Kevin RC, Martin L, Adams A, Macdonald C, Manning JJ, Boyd R, Cunningham M, Stevens MY, McGregor IS, Glass M, Connor M, Gerona RR.

Drug Test Anal. 2019 Jul;11(7):976-989. doi: 10.1002/dta.2583. Epub 2019 May 8.

PMID:
30838752
7.

Dark Classics in Chemical Neuroscience: Δ9-Tetrahydrocannabinol.

Banister SD, Arnold JC, Connor M, Glass M, McGregor IS.

ACS Chem Neurosci. 2019 May 15;10(5):2160-2175. doi: 10.1021/acschemneuro.8b00651. Epub 2019 Feb 22.

PMID:
30689342
8.

Structure of a Signaling Cannabinoid Receptor 1-G Protein Complex.

Krishna Kumar K, Shalev-Benami M, Robertson MJ, Hu H, Banister SD, Hollingsworth SA, Latorraca NR, Kato HE, Hilger D, Maeda S, Weis WI, Farrens DL, Dror RO, Malhotra SV, Kobilka BK, Skiniotis G.

Cell. 2019 Jan 24;176(3):448-458.e12. doi: 10.1016/j.cell.2018.11.040. Epub 2019 Jan 10.

PMID:
30639101
9.

An outbreak of synthetic cannabinoid exposures reported to a regional poison center: "K2" identified as 5F-ADB.

Arens AM, Olives TD, Simpson NS, Laes JR, Anderson DL, Bangh SA, Lee SC, Martin S, Banister SD, Gerona RR, Cole JB.

Clin Toxicol (Phila). 2019 Jan;57(1):69-71. doi: 10.1080/15563650.2018.1497170. Epub 2018 Nov 15. No abstract available.

PMID:
30430881
10.

Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold- hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA.

Banister SD, Adams A, Kevin RC, Macdonald C, Glass M, Boyd R, Connor M, McGregor IS, Havel CM, Bright SJ, Vilamala MV, Lladanosa CG, Barratt MJ, Gerona RR.

Drug Test Anal. 2019 Feb;11(2):279-291. doi: 10.1002/dta.2491. Epub 2018 Oct 1.

PMID:
30151911
11.

The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution.

Banister SD, Connor M.

Handb Exp Pharmacol. 2018;252:191-226. doi: 10.1007/164_2018_144.

PMID:
30105473
12.

The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins.

Banister SD, Connor M.

Handb Exp Pharmacol. 2018;252:165-190. doi: 10.1007/164_2018_143. Review.

PMID:
29980914
13.

The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs.

Banister SD, Olson A, Winchester M, Stuart J, Edington AR, Kevin RC, Longworth M, Herrera M, Connor M, McGregor IS, Gerona RR, Kassiou M.

Drug Test Anal. 2018 Jan 19. doi: 10.1002/dta.2362. [Epub ahead of print]

PMID:
29350472
14.

In vitro and in vivo metabolite identification of a novel benzimidazole compound ZLN005 by LC-MS/MS.

Sun W, Nguyen KD, Fitch WL, Banister SD, Tang H, Zhang X, Yu L, Engleman EG, Rajadas J.

Rapid Commun Mass Spectrom. 2018 Jan 15. doi: 10.1002/rcm.8060. [Epub ahead of print]

PMID:
29334584
15.

Synthetic cannabinoid "Black Mamba" infidelity in patients presenting for emergency stabilization in Colorado: a P SCAN Cohort.

Brandehoff N, Adams A, McDaniel K, Banister SD, Gerona R, Monte AA.

Clin Toxicol (Phila). 2018 Mar;56(3):193-198. doi: 10.1080/15563650.2017.1357826. Epub 2017 Sep 1.

16.

Pharmacology of Cumyl-Carboxamide Synthetic Cannabinoid New Psychoactive Substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and Their Analogues.

Longworth M, Banister SD, Boyd R, Kevin RC, Connor M, McGregor IS, Kassiou M.

ACS Chem Neurosci. 2017 Oct 18;8(10):2159-2167. doi: 10.1021/acschemneuro.7b00267. Epub 2017 Aug 11.

PMID:
28792725
17.

Synthesis and Pharmacological Profiling of the Metabolites of Synthetic Cannabinoid Drugs APICA, STS-135, ADB-PINACA, and 5F-ADB-PINACA.

Longworth M, Connor M, Banister SD, Kassiou M.

ACS Chem Neurosci. 2017 Aug 16;8(8):1673-1680. doi: 10.1021/acschemneuro.7b00116. Epub 2017 Jun 8.

PMID:
28574245
18.

"Zombie" Outbreak Caused by Synthetic Cannabinoid.

Gerona R, Adams A, Banister SD.

N Engl J Med. 2017 Apr 20;376(16):1597-8. doi: 10.1056/NEJMc1701936. No abstract available.

PMID:
28423302
19.

Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples.

Mogler L, Franz F, Rentsch D, Angerer V, Weinfurtner G, Longworth M, Banister SD, Kassiou M, Moosmann B, Auwärter V.

Drug Test Anal. 2018 Jan;10(1):196-205. doi: 10.1002/dta.2201. Epub 2017 May 24.

PMID:
28371476
20.

Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA.

Kevin RC, Wood KE, Stuart J, Mitchell AJ, Moir M, Banister SD, Kassiou M, McGregor IS.

J Psychopharmacol. 2017 Jun;31(6):757-769. doi: 10.1177/0269881116684336. Epub 2017 Jan 16.

PMID:
28093016
21.

"Zombie" Outbreak Caused by the Synthetic Cannabinoid AMB-FUBINACA in New York.

Adams AJ, Banister SD, Irizarry L, Trecki J, Schwartz M, Gerona R.

N Engl J Med. 2017 Jan 19;376(3):235-242. doi: 10.1056/NEJMoa1610300. Epub 2016 Dec 14.

22.

Derivatives of the pyrazolo[1,5-a]pyrimidine acetamide DPA-713 as translocator protein (TSPO) ligands and pro-apoptotic agents in human glioblastoma.

Werry EL, King VA, Barron ML, Banister SD, Sokias R, Kassiou M.

Eur J Pharm Sci. 2017 Jan 1;96:186-192. doi: 10.1016/j.ejps.2016.09.026. Epub 2016 Sep 19.

PMID:
27658888
23.

Increase in Adverse Reactions Associated with Use of Synthetic Cannabinoids - Anchorage, Alaska, 2015-2016.

Springer YP, Gerona R, Scheunemann E, Shafer SL, Lin T, Banister SD, Cooper MP, Castrodale LJ, Levy M, Butler JC, McLaughlin JB.

MMWR Morb Mortal Wkly Rep. 2016 Oct 14;65(40):1108-1111. doi: 10.15585/mmwr.mm6540a4.

24.

A systematic exploration of the effects of flexibility and basicity on sigma (σ) receptor binding in a series of substituted diamines.

Conroy T, Manohar M, Gong Y, Wilkinson SM, Webster M, Lieberman BP, Banister SD, Reekie TA, Mach RH, Rendina LM, Kassiou M.

Org Biomol Chem. 2016 Oct 4;14(39):9388-9405.

PMID:
27714195
25.

The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities.

Longworth M, Banister SD, Mack JBC, Glass M, Connor M, Kassiou M.

Forensic Toxicol. 2016;34:286-303. doi: 10.1007/s11419-016-0316-y. Epub 2016 Apr 27.

26.

Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues.

Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, Mack JB, Glass M, McGregor IS, Connor M, Kassiou M.

ACS Chem Neurosci. 2016 Sep 21;7(9):1241-54. doi: 10.1021/acschemneuro.6b00137. Epub 2016 Jul 27.

PMID:
27421060
27.
28.

The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.

Beinat C, Banister SD, Herrera M, Law V, Kassiou M.

CNS Drugs. 2015 Jul;29(7):529-42. doi: 10.1007/s40263-015-0260-0. Review.

PMID:
26242477
29.

Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA.

Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Glass M, Connor M, McGregor IS, Kassiou M.

ACS Chem Neurosci. 2015 Sep 16;6(9):1546-59. doi: 10.1021/acschemneuro.5b00112. Epub 2015 Jul 17.

PMID:
26134475
30.

Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135.

Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M.

ACS Chem Neurosci. 2015 Aug 19;6(8):1445-58. doi: 10.1021/acschemneuro.5b00107. Epub 2015 May 8.

PMID:
25921407
31.

Structure-activity relationship studies of SEN12333 analogues: determination of the optimal requirements for binding affinities at α7 nAChRs through incorporation of known structural motifs.

Beinat C, Reekie T, Banister SD, O'Brien-Brown J, Xie T, Olson TT, Xiao Y, Harvey A, O'Connor S, Coles C, Grishin A, Kolesik P, Tsanaktsidis J, Kassiou M.

Eur J Med Chem. 2015 May 5;95:277-301. doi: 10.1016/j.ejmech.2015.03.025. Epub 2015 Mar 14.

PMID:
25827398
32.

Ether analogues of DPA-714 with subnanomolar affinity for the translocator protein (TSPO).

Banister SD, Beinat C, Wilkinson SM, Shen B, Bartoli C, Selleri S, Da Pozzo E, Martini C, Chin FT, Kassiou M.

Eur J Med Chem. 2015 Mar 26;93:392-400. doi: 10.1016/j.ejmech.2015.02.004. Epub 2015 Feb 7.

PMID:
25725375
33.

Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-induced hyperlocomotion in adulthood: amelioration by COX-2 inhibition.

Zavitsanou K, Lim CK, Purves-Tyson T, Karl T, Kassiou M, Banister SD, Guillemin GJ, Weickert CS.

Brain Behav Immun. 2014 Oct;41:173-81. doi: 10.1016/j.bbi.2014.05.011. Epub 2014 May 27.

PMID:
24878170
34.

Structure-activity relationships of N-substituted 4-(trifluoromethoxy)benzamidines with affinity for GluN2B-containing NMDA receptors.

Beinat C, Banister SD, Hoban J, Tsanaktsidis J, Metaxas A, Windhorst AD, Kassiou M.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):828-30. doi: 10.1016/j.bmcl.2013.12.087. Epub 2013 Dec 28.

PMID:
24412068
35.

The development of radiotracers for imaging sigma (σ) receptors in the central nervous system (CNS) using positron emission tomography (PET).

Banister SD, Manoli M, Kassiou M.

J Labelled Comp Radiopharm. 2013 Mar-Apr;56(3-4):215-24. doi: 10.1002/jlcr.3010. Review.

PMID:
24285328
36.

N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as σ receptor ligands with potential neuroprotective effects.

Banister SD, Manoli M, Barron ML, Werry EL, Kassiou M.

Bioorg Med Chem. 2013 Oct 1;21(19):6038-52. doi: 10.1016/j.bmc.2013.07.045. Epub 2013 Aug 6.

PMID:
23981939
37.

The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse.

Banister SD, Wilkinson SM, Longworth M, Stuart J, Apetz N, English K, Brooker L, Goebel C, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M.

ACS Chem Neurosci. 2013 Jul 17;4(7):1081-92. doi: 10.1021/cn400035r. Epub 2013 Apr 17.

38.

[18F]DPA-714: direct comparison with [11C]PK11195 in a model of cerebral ischemia in rats.

Boutin H, Prenant C, Maroy R, Galea J, Greenhalgh AD, Smigova A, Cawthorne C, Julyan P, Wilkinson SM, Banister SD, Brown G, Herholz K, Kassiou M, Rothwell NJ.

PLoS One. 2013;8(2):e56441. doi: 10.1371/journal.pone.0056441. Epub 2013 Feb 13.

39.

A σ(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).

Banister SD, Manoli M, Doddareddy MR, Hibbs DE, Kassiou M.

Bioorg Med Chem Lett. 2012 Oct 1;22(19):6053-8. doi: 10.1016/j.bmcl.2012.08.046. Epub 2012 Aug 21.

PMID:
22959245
40.

Exploration of ring size in a series of cyclic vicinal diamines with σ₁ receptor affinity.

Moussa IA, Banister SD, Manoli M, Doddareddy MR, Cui J, Mach RH, Kassiou M.

Bioorg Med Chem Lett. 2012 Sep 1;22(17):5493-7. doi: 10.1016/j.bmcl.2012.07.026. Epub 2012 Jul 14.

PMID:
22850210
41.

7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (σ2) receptor ligands.

Banister SD, Rendina LM, Kassiou M.

Bioorg Med Chem Lett. 2012 Jun 15;22(12):4059-63. doi: 10.1016/j.bmcl.2012.04.077. Epub 2012 Apr 30.

PMID:
22607684
42.

Consequences of linker length alteration of the α7 nicotinic acetylcholine receptor (nAChR) agonist, SEN12333.

Beinat C, Banister SD, van Prehn S, Doddareddy MR, Hibbs D, Sako M, Chebib M, Tran T, Al-Muhtasib N, Xiao Y, Kassiou M.

Bioorg Med Chem Lett. 2012 Apr 1;22(7):2380-4. doi: 10.1016/j.bmcl.2012.02.052. Epub 2012 Feb 24.

PMID:
22410083
43.
44.

Synthesis and in vivo evaluation of [18F]N-(2-benzofuranylmethyl)-N'-[4-(2-fluoroethoxy)benzyl]piperazine, a novel σ1 receptor PET imaging agent.

Moussa IA, Banister SD, Giboureau N, Meikle SR, Kassiou M.

Bioorg Med Chem Lett. 2011 Nov 15;21(22):6820-3. doi: 10.1016/j.bmcl.2011.09.028. Epub 2011 Sep 13.

PMID:
21962578
45.

Effects of linker elongation in a series of N-(2-benzofuranylmethyl)-N'-(methoxyphenylalkyl)piperazine σ₁ receptor ligands.

Moussa IA, Banister SD, Akladios FN, Chua SW, Kassiou M.

Bioorg Med Chem Lett. 2011 Oct 1;21(19):5707-10. doi: 10.1016/j.bmcl.2011.08.029. Epub 2011 Aug 12.

PMID:
21871797
46.

N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (σ) receptor ligands.

Banister SD, Yoo DT, Chua SW, Cui J, Mach RH, Kassiou M.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5289-92. doi: 10.1016/j.bmcl.2011.07.028. Epub 2011 Jul 14.

PMID:
21788137
47.

Molecular hybridization of 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecane-3-ol with sigma (σ) receptor ligands modulates off-target activity and subtype selectivity.

Banister SD, Moussa IA, Jorgensen WT, Chua SW, Kassiou M.

Bioorg Med Chem Lett. 2011 Jun 15;21(12):3622-6. doi: 10.1016/j.bmcl.2011.04.098. Epub 2011 Apr 28.

PMID:
21555222
48.

Trishomocubane as a scaffold for the development of selective dopamine transporter (DAT) ligands.

Banister SD, Moussa IA, Beinat C, Reynolds AJ, Schiavini P, Jorgensen WT, Kassiou M.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):38-41. doi: 10.1016/j.bmcl.2010.11.075. Epub 2010 Nov 21.

PMID:
21146989
49.

Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands.

Moussa IA, Banister SD, Beinat C, Giboureau N, Reynolds AJ, Kassiou M.

J Med Chem. 2010 Aug 26;53(16):6228-39. doi: 10.1021/jm100639f.

PMID:
20662542
50.

11-{[2-(3-Fluoro-phen-yl)eth-yl](meth-yl)amino}-penta-cyclo-[5.4.0.0.0.0]undecan-8-one.

Banister SD, Clegg JK, Hanani R, Kassiou M.

Acta Crystallogr Sect E Struct Rep Online. 2010 Sep 30;66(Pt 10):o2693. doi: 10.1107/S1600536810038523.

Supplemental Content

Loading ...
Support Center